Stifel Reiterates Buy Rating on Crinetics (CRNX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Crinetics (CRNX) PT Raised to $80 at Morgan Stanley
January 5, 2026 1:44 PM ESTMorgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $80.00 (from $77.00) while maintaining a Overweight rating.
The analyst comments "We see atumelnant data continuing to demonstrate potential best-in-class efficacy, with no hepatic transaminase AEs. Nearterm, we expect investor... More
